|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.78 USD | +2.79% |
|
+10.02% | +13.75% |
| 01-07 | UBS Adjusts Price Target on Denali Therapeutics to $25 From $24, Maintains Buy Rating | MT |
| 01-06 | Denali Therapeutics announces key anticipated milestones and priorities for 2026 | RE |
| Capitalization | 2.93B 2.53B 2.35B 2.19B 4.07B 265B 4.37B 27.05B 10.64B 127B 11B 10.77B 465B | P/E ratio 2025 * |
-6.34x | P/E ratio 2026 * | -6.56x |
|---|---|---|---|---|---|
| Enterprise value | 2.32B 2B 1.87B 1.74B 3.23B 210B 3.46B 21.43B 8.43B 100B 8.71B 8.53B 368B | EV / Sales 2025 * |
871x | EV / Sales 2026 * | 37.7x |
| Free-Float |
90.34% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Denali Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | +2.79% | ||
| 1 week | +10.02% | ||
| Current month | +13.75% | ||
| 1 month | +8.30% | ||
| 3 months | +15.14% | ||
| 6 months | +32.53% | ||
| Current year | +13.75% |
| 1 week | 16.96 |  | 18.98 |
| 1 month | 15.34 | | 18.98 |
| Current year | 15.34 | | 18.98 |
| 1 year | 10.57 | | 24.34 |
| 3 years | 10.57 | | 33.33 |
| 5 years | 10.57 | | 83.98 |
| 10 years | 10.57 | | 93.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
DFI | Director of Finance/CFO | 52 | 30/04/2022 |
Ryan Watts
CEO | Chief Executive Officer | 50 | 31/07/2015 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Watts
BRD | Director/Board Member | 50 | 28/02/2015 |
| Chairman | 66 | 28/02/2015 | |
Jay Flatley
BRD | Director/Board Member | 73 | 31/03/2015 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +1.16% | 0.07% | 2,091 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.79% | +10.02% | -12.65% | -35.44% | 2.85B | |
| +0.90% | 0.00% | +8.53% | +87.92% | 49.27B | |
| +0.15% | +5.49% | +94.37% | +13.80% | 44.15B | |
| -2.56% | -6.46% | +126.88% | +718.87% | 34.86B | |
| -2.80% | +7.30% | -6.69% | -26.87% | 27.38B | |
| -3.86% | +0.65% | +45.67% | -21.71% | 21.63B | |
| -1.20% | +7.18% | +123.90% | -46.25% | 21.21B | |
| -2.13% | -6.43% | +109.66% | +145.68% | 14.58B | |
| -0.94% | -1.93% | +192.37% | - | 13.95B | |
| -2.15% | -8.28% | -5.11% | +259.79% | 13.61B | |
| Average | -1.10% | +1.57% | +67.69% | +121.75% | 24.35B | |
| Weighted average by Cap. | -1.13% | +1.30% | +68.25% | +145.40% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.67M 2.3M 2.14M 1.99M 3.7M 241M 3.97M 24.6M 9.68M 115M 10M 9.79M 423M | 63.46M 54.67M 50.95M 47.4M 88.18M 5.73B 94.59M 585M 230M 2.74B 238M 233M 10.06B |
| Net income | -515M -443M -413M -385M -715M -46.52B -767M -4.75B -1.87B -22.24B -1.93B -1.89B -81.58B | -515M -444M -414M -385M -716M -46.57B -768M -4.75B -1.87B -22.26B -1.93B -1.89B -81.67B |
| Net Debt | -609M -525M -489M -455M -847M -55.06B -908M -5.62B -2.21B -26.32B -2.29B -2.24B -96.57B | -540M -465M -433M -403M -750M -48.78B -805M -4.98B -1.96B -23.32B -2.02B -1.98B -85.56B |
More financial data
* Estimated data
Employees
517
Calendar
02-02
- WORLD Symposium
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 18.78 $ | +2.79% | 1,894,543 |
| 14/01/26 | 18.27 $ | +0.88% | 1,128,570 |
| 13/01/26 | 18.11 $ | +0.89% | 1,225,568 |
| 12/01/26 | 17.95 $ | +5.09% | 1,144,672 |
| 09/01/26 | 17.08 $ | +0.06% | 987,124 |
Delayed Quote Nasdaq, January 15, 2026 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
18.78USD
Average target price
32.86USD
Spread / Average Target
+74.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DNLI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition